Skip to main
EVMN

Evommune Inc (EVMN) Stock Forecast & Price Target

Evommune Inc (EVMN) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 63%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evommune is in a unique position to address the needs of patients with chronic inflammatory diseases through its differentiated pipeline targeting key drivers of disease. EVO756, the company's MRGPRX2 antagonist, has shown promise in clinical trials for chronic inducible urticaria (CIndU) and could potentially have a significant market opportunity in chronic spontaneous urticaria (CSU). EVO301, an IL-18 fusion protein inhibitor, also has potential in AD and UC. The company's strong pipeline, coupled with positive clinical data and potential for expansion into additional indications, make it an attractive investment opportunity.

Bears say

Evommune is currently in its early stages of clinical development, with its lead asset EVO756 targeting chronic spontaneous urticaria (CSU) and atopic dermatitis (AD). While the company may have promising early signals for EVO756 and IL-18 '301, the potential for '756 in other indications such as migraine appears overlooked with concerns around safety, expenses, and non-revenue-generating status. Estimated 2035E global sales of $1.7B for EVO756/CSU and $1.5B for EVO301/AD could potentially support a valuation of $42 per share, but there remain unmet needs in the market and potential risks with other approved therapies.

Evommune Inc (EVMN) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 63% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evommune Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evommune Inc (EVMN) Forecast

Analysts have given Evommune Inc (EVMN) a Buy based on their latest research and market trends.

According to 8 analysts, Evommune Inc (EVMN) has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evommune Inc (EVMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.